It is noted that cost-effectiveness is improved when we considered the impact of pathways on lower GI, uterine, lung and pancreatic cancers, as evidence suggests that, in addition to OC, CA125 levels are often raised in women with a range of cancers, with the four included cancer types being particularly associated with CA125 elevations [8]. This evidence concerns the gene MUC16 and cancer.